Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Dermatologic 1CNS 1

Conditions

Glioblastoma 380Brain Neoplasms 376Glioma 232Gliosarcoma 147Astrocytoma 138Neuroblastoma 121Central Nervous System Neoplasms 118Oligodendroglioma 80Medulloblastoma 61Breast Neoplasms 52Neoplasms 51Melanoma 45Ependymoma 43Carcinoma, Non-Small-Cell Lung 42Recurrence 40Sarcoma 33Meningioma 33Rhabdomyosarcoma 32Neurofibromatosis 1 32Osteosarcoma 31Neoplasm Metastasis 29Lymphoma, Non-Hodgkin 27Wilms Tumor 26Lung Neoplasms 26Neuroectodermal Tumors, Primitive, Peripheral 25Sarcoma, Ewing 23Lymphoma 22Rhabdoid Tumor 20Hepatoblastoma 19Testicular Neoplasms 17

Interventions

Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Histiocytoma × CNS × Clear all
NCT01962103 2019-12-27

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

Celgene

Phase 1/2 Completed
107 enrolled 42 charts
CNSDermatologicSarcoma

Fibrosarcoma, Melanoma, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Dermatofibrosarcoma, Histiocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡